Arrêt de service programmé du vendredi 10 juin 16h jusqu’au lundi 13 juin 9h. Pour en savoir plus
Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

The evolution of nucleosidic analogues: self-assembly of prodrugs into nanoparticles for cancer drug delivery

Abstract : Nucleoside and nucleotide analogs are essential tools in our limited arsenal in the fight against cancer. However, these structures face severe drawbacks such as rapid plasma degradation or hydrophilicity, limiting their clinical application. Here, different aspects of nucleoside and nucleotide analogs have been exposed, while providing their shortcomings. Aiming to improve their fate in the body and combating their drawbacks, two different approaches have been discussed, the prodrug and nanocarrier technologies. Finally, a novel approach called "PUFAylation" based on both the prodrug and nanocarrier technologies has been introduced, promising to be the supreme method to create a novel nucleoside or nucleotide analog based formulation, with enhanced efficacy and highly reduced toxicity.
Liste complète des métadonnées

https://hal.univ-angers.fr/hal-03448613
Contributeur : Laurent Lemaire Connectez-vous pour contacter le contributeur
Soumis le : jeudi 25 novembre 2021 - 11:38:25
Dernière modification le : mercredi 27 avril 2022 - 03:56:52
Archivage à long terme le : : samedi 26 février 2022 - 18:39:52

Fichier

Baroud M et al., Nanoscale adv...
Fichiers éditeurs autorisés sur une archive ouverte

Licence


Distributed under a Creative Commons Paternité - Pas d'utilisation commerciale 4.0 International License

Identifiants

Citation

Milad Baroud, Elise Lepeltier, Sylvain Thepot, Yolla El-Makhour, Olivier Duval. The evolution of nucleosidic analogues: self-assembly of prodrugs into nanoparticles for cancer drug delivery. Nanoscale Advances, RSC, 2021, 3 (8), pp.2157 - 2179. ⟨10.1039/d0na01084g⟩. ⟨hal-03448613⟩

Partager

Métriques

Consultations de la notice

27

Téléchargements de fichiers

17